Cargando…
B7-H3 in Brain Malignancies: Immunology and Immunotherapy
The immune checkpoint B7-H3 (CD276), a member of the B7 family with immunoregulatory properties, has been identified recently as a novel target for immunotherapy for refractory blood cancers and solid malignant tumors. While research on B7-H3 in brain malignancies is limited, there is growing intere...
Autores principales: | Guo, Xiaopeng, Chang, Mengqi, Wang, Yu, Xing, Bing, Ma, Wenbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411461/ https://www.ncbi.nlm.nih.gov/pubmed/37564196 http://dx.doi.org/10.7150/ijbs.85813 |
Ejemplares similares
-
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
por: Zhao, Binghao, et al.
Publicado: (2022) -
Classification of pediatric gliomas based on immunological profiling: implications for immunotherapy strategies
por: Wang, Zihao, et al.
Publicado: (2020) -
Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients
por: Wang, Zihao, et al.
Publicado: (2020) -
Editorial: New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Tumor Immunology and Immunotherapy
por: Seiffert, Martina, et al.
Publicado: (2022) -
Hopes on immunotherapy targeting B7-H3 in neuroblastoma
por: Pulido, Rafael, et al.
Publicado: (2022)